Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

primary non-gestational choriocarcinoma of ovary (NGCO) - Clinical Profile, Genes & Research | Kisho | Kisho

Rare Disease

primary non-gestational choriocarcinoma of ovary

MONDO:0017327

Also known as:NGCOprimary non-gestational ovarian choriocarcinoma

Overview

Primary non-gestational choriocarcinoma of ovary is a rare ovarian germ cell malignant tumor, arising from primordial germ cells, usually presenting with nausea, vomiting, abdominal pain, menstrual irregularities, and characterized by fast growth pattern, metastasis to lung, liver and brain and production of human chorionic gonadotrophin (hCG). It is apparently chemoresistant and has a worse prognosis than gestational choriocarcinoma and hence should be distinguished from the latter by DNA polymorphism.

ResearchLimited published research (6 articles)

Prognosis

Estimated prevalence: Unknown (Unknown prevalence).

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

No clinical trials have been registered for primary non-gestational choriocarcinoma of ovary.

6 publications have been identified in PubMed for primary non-gestational choriocarcinoma of ovary. Research spans Review / Meta-Analysis (50%) and Case Report / Case Series (50%).

Recent Publications

Ordoñez Arrillaga A (2026). [PMID: 41579581](https://pubmed.ncbi.nlm.nih.gov/41579581/). *Rev Esp Patol*. [Review / Meta-Analysis]
Kara SS (2025). [PMID: 39090978](https://pubmed.ncbi.nlm.nih.gov/39090978/). *Int J Surg Pathol*. [Case Report / Case Series]
Ma J (2025). [PMID: 41195577](https://pubmed.ncbi.nlm.nih.gov/41195577/). *Cancer Rep (Hoboken)*. [Review / Meta-Analysis]
Garcia Pleitez H (2024). [PMID: 39372162](https://pubmed.ncbi.nlm.nih.gov/39372162/). *Eur J Case Rep Intern Med*. [Case Report / Case Series]
Huang M (2024). [PMID: 39434070](https://pubmed.ncbi.nlm.nih.gov/39434070/). *BMC Womens Health*. [Case Report / Case Series]

Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 12:51 AM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

External Resources

Orphanet

European rare disease database

Orphanet:289356

GARD

Genetic and Rare Diseases Info Center

GARD:21136

Questions for Your Care Team

→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Kisho

primary non-gestational choriocarcinoma of ovary

Overview

Prognosis

Research Landscape

Recent Publications

Medical References

External Resources

Orphanet

GARD

Questions for Your Care Team

Questions for Your Care Team

Latest News & Developments

Targeting the GSK-3β/mTOR axis to overcome chemoresistance in gestational choriocarcinoma: molecular mechanisms and therapeutic opportunities.

primary non-gestational choriocarcinoma of ovary

Overview

Prognosis

Research Landscape

Recent Publications

Medical References

External Resources

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Latest News & Developments

Targeting the GSK-3β/mTOR axis to overcome chemoresistance in gestational choriocarcinoma: molecular mechanisms and therapeutic opportunities.